Publications by authors named "Qichun Nian"
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab.
Expert Opin Drug Saf
December 2024
Background: Ramucirumab (IMC-1121B) is a fully human immunoglobulin G1 monoclonal antibody, approved by the US Food and Drug Administration (FDA) for treating various cancers, including gastric, colorectal, liver, and non-small cell lung cancer. This study aimed to investigate the adverse events (AEs) associated with ramucirumab by utilizing data mining techniques on the FDA Adverse Event Reporting System (FAERS).
Methods: We collected ramucirumab-related data from the FAERS database, spanning from January 2014 to June 2023.
Article Synopsis
- Asciminib is a drug used mainly for treating chronic myeloid leukemia in patients with specific mutations or those who have undergone prior treatments; however, its long-term safety isn't well established.
- This study analyzed adverse events linked to asciminib using the FDA's adverse event reporting system from October 2021 to December 2023, identifying over 900 reported incidents.
- Findings revealed 26 significant adverse events related to off-label use of asciminib, with a median onset of 52.5 days, suggesting a need for further research on its safety profile.
In this study, we delved into the safety profile of alpelisib, an FDA-approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, and PIK3CA-Related Overgrowth Spectrum (PROS). Despite its approval, real-world, long-term safety data is lacking. Our research scrutinizes the FDA database to assess alpelisib 's safety.
View Article and Find Full Text PDF